Avicanna Inc. (AVCNF)

0.3006 0.0000 (0.00%) At close: 11:36AM EDT

Avicanna Inc.

480 University Avenue
Suite 1502
Toronto, ON M5G 1V2
Canada

https://www.avicanna.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 87

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Aras Azadian B.Econ, Mba	Co-Founder, CEO & Director	117.72k	N/A	N/A
Mr. Phillip Cardella C.A., CPA	Chief Financial Officer	104.49k	N/A	N/A
Dr. Frantz Le Devedec	Executive Vice President of Research & Development	96.62k	N/A	N/A
Mr. Stephen Kim	Chief Legal Officer & General Counsel of Avicanna USA Inc.	150.15k	N/A	N/A
Mr. Arash Moghani MBA	Executive Vice President of Operations & Technology	N/A	N/A	N/A
Ms. Ingrid Diaz	VP, Assistant General Counsel & Corporate Compliance Officer	N/A	N/A	N/A
Ms. Ivana Maric	Executive Vice President of Marketing	N/A	N/A	N/A
Mr. Enric Pujol	Vice President of People	N/A	N/A	N/A
Dr. Carlos Enrique Maldonado Muete	SVP of Clinical Development	N/A	N/A	N/A
Dr. Karolina Urban	Executive Vice President of Scientific & Medical Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Corporate governance

Avicanna Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.